Literature DB >> 18471998

Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus.

Yih-Hsin Chang1, I-Ling Lin, Gregory J Tsay, Shun-Chun Yang, Tzi-Peng Yang, Kuo-Ting Ho, Tsai-Ching Hsu, Ming-Yuh Shiau.   

Abstract

OBJECTIVES: Matrix metalloproteinases (MMPs) are suggested to play important roles in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This study is to examine the MMPs expressions and activities in Taiwanese RA and SLE patients. DESIGN AND METHODS: Levels and activities of plasma MMP-2 and MMP-9 were investigated by enzyme-linked immunosorbent assay and zymography, respectively.
RESULTS: MMP-2 levels in control subjects, RA and SLE patients were 146.1+/-34.2, 194.0+/-24.2 and 208.9+/-75.9 ng/mL respectively, and for MMP-9 were 51.4+/-57.1, 567.7+/-313.1 and 208.7+/-105.5 ng/mL respectively. Both MMP-2 and MMP-9 levels and activities from all patients were significantly higher than that from control subjects.
CONCLUSIONS: MMP-2 levels in both patients groups were approximately 1.3-1.4 folds higher than that in control subjects, notably, MMP-9 levels were 11- and 4-folds significantly higher, respectively, in RA and SLE patients. The results which MMP-2 and MMP-9 levels and activities are significantly elevated support the involvement of MMPs proteins in these autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471998     DOI: 10.1016/j.clinbiochem.2008.04.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  32 in total

1.  CD14 signaling reciprocally controls collagen deposition and turnover to regulate the development of lyme arthritis.

Authors:  Bikash Sahay; Anju Singh; Arumugam Gnanamani; Rebeca L Patsey; J Edwin Blalock; Timothy J Sellati
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.

Authors:  A C Maretti-Mira; M P de Oliveira-Neto; A M Da-Cruz; M P de Oliveira; N Craft; C Pirmez
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

3.  Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype.

Authors:  Jelena Basic; Dusica Pavlovic; Tatjana Jevtovic-Stoimenov; Jelena Vojinovic; Gordana Susic; Ivana Stojanovic; Gordana Kocic; Vuk Milosevic; Tatjana Cvetkovic; Milena Marinkovic; Andrej Veljkovic
Journal:  J Physiol Biochem       Date:  2010-07-02       Impact factor: 4.158

Review 4.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

5.  Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Authors:  Ali Azhdarinia; Nathaniel Wilganowski; Holly Robinson; Pradip Ghosh; Sunkuk Kwon; Zawaunyka W Lazard; Alan R Davis; Elizabeth Olmsted-Davis; Eva M Sevick-Muraca
Journal:  Bioorg Med Chem       Date:  2011-05-06       Impact factor: 3.641

6.  Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis.

Authors:  Rajesh Rajaiah; Muraly Puttabyatappa; Swamy K Polumuri; Kamal D Moudgil
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

7.  Fluorescent water soluble polymers for isozyme-selective interactions with matrix metalloproteinase-9.

Authors:  Rinku Dutta; Michael D Scott; Manas K Haldar; Bratati Ganguly; D K Srivastava; Daniel L Friesner; Sanku Mallik
Journal:  Bioorg Med Chem Lett       Date:  2011-02-28       Impact factor: 2.823

8.  Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis.

Authors:  Zhongxin Jiang; Tao Sui; Bin Wang
Journal:  Rheumatol Int       Date:  2009-09-25       Impact factor: 2.631

9.  Immunolocalization of MMP-2 and MMP-9 in human rheumatoid synovium.

Authors:  Meng Zhou; Si Qin; Yang Chu; Fengming Wang; Lujun Chen; Yahua Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.